Table 2.

Success rates in the Autologous Conditioned Serum (ACS), ACS+Cortisone (ACS+C), and ACS+C+recombinant IL-1 receptor antagonist protein (ACS+C+rIRAP) groups.

	Total		Mild OA		Severe OA
Overall	N=150	119 (79.3%)	N=96	74 (77.1%)	N=54	45 (83.3%)
ACS	N=62	51 (82.3%)	N=46	35 (76.1%)	N=16	16 (100%)
ACS+C	N=71	52 (73.2%)	N=41	30 (73.2%)	N=30	22 (73.3%)
ACS+C+rIRAP	N=17	16 (94.1%)	N=9	9 (100%)	N=8	7 (87.5%)
P		0.14		0.27		0.06
Effect size (ω)		0.17		0.18		0.30
Power (1-β)		0.45		0.33		0.49

N, number of hips; OA, Osteoarthritis; Mild, Kellgren/Lawrence (K/L) hip grade 2-3; Severe=K/L hip grade 4; VAS, Visual Analogue Scale (0=no pain, 10=most severe pain).

Success was defined by VAS pain reduction, i.e. a positive difference between a patient’s pre- and post-treatment VAS score, of at least 20%. The figures represent absolute frequencies (%), P values were calculated by Fisher’s exact tests with the effect size ω(≥0.50=large, ≥0.30=moderate, ≥0.10=small). Power ≥0.80=large.